-
-
-
-
-
-
-
BrainStorm Cell Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
BrainStorm Cell Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
Brainstorm Cell Therapeutics (BCLI) Announces Peer-reviewed Publication of Biomarker Data from NurOwn's® Phase 3 Clinical Trial in ALS
-
-
-
-
-
-
-
BrainStorm Cell Therapeutics to Unveil Phase 3b NurOwn® Trial Design at MDA Clinical and Scientific Conference
-
-
-
-
-
-
-
BrainStorm Issues 2023 Letter to Shareholders
-
-
-
-
-
-
-
BrainStorm Cell Therapeutics Stock Trading Halted Today
-
-
-
-
-
-
-
BrainStorm Cell Therapeutics Announces FDA Advisory Committee Meeting to Review NurOwn® Biologics License Application Scheduled for September 27, 2023
-
15,627 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

